Crinetics-Vertex merger clears HSR and key antitrust hurdles; close expected early Sept

Crinetics Pharmaceuticals, Inc.

HSR waiting period expired Aug 12, 2026 at 12:45 p.m. ET.
Antitrust approvals received in Austria, Germany, Australia; Australia waiting period expires Aug 27, 2026.
Shareholder vote scheduled for Aug 28, 2026; merger expected to close early September 2026.
Deal projected to support >$5B annual revenue and be accretive to non-GAAP operating income in 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.